

Molecular Cancer Therapeutics

A Journal of the American Association for Cancer Research

Volume 7, Number 7

July 2008

Research Articles: Therapeutics, Targets, and Development

- Laser postionization secondary neutral mass spectrometry in tissue: a powerful tool for elemental and molecular imaging in the development of targeted drugs**1763
Andrea Wittig, Heinrich F. Arlinghaus, Christian Kriegeskotte, Raymond L. Moss, Klaas Appelman, Kurt W. Schmid, and Wolfgang A.G. Sauerwein
- Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair**1772
Mahmoud Toulany, Rainer Kehlbach, Urszula Florczak, Ali Sak, Shaomeng Wang, Jianyong Chen, Markus Loblrich, and H. Peter Rodemann
- eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling**1782
Alpana Soni, Argun Akcakanat, Gopal Singh, David Luyimbazi, Yuhuan Zheng, Doyil Kim, Ana Gonzalez-Angulo, and Funda Meric-Bernstam
- Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways**1789
Tingfang Yi, Sung-Gook Cho, Zhengfang Yi, Xiufeng Pang, Melissa Rodriguez, Ying Wang, Gautam Sethi, Bharat B. Aggarwal, and Mingyao Liu
- Antiproliferative effect of sulindac in colonic neoplasia prevention: role of COOH-terminal Src kinase**1797
Dhananjay P. Kunte, Ramesh K. Wali, Jennifer L. Koetsier, and Hemant K. Roy
- Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma**1807
Hui Guan, Zhichao Zhou, Gary E. Gallick, Shu-Fang Jia, Jaime Morales, Anil K. Sood, Seth J. Corey, and Eugenie S. Kleinerman
- Silibinin inhibits cytokine-induced signaling cascades and down-regulates inducible nitric oxide synthase in human lung carcinoma A549 cells**1817
Manesh Chittezhath, Gagan Deep, Rana P. Singh, Chapla Agarwal, and Rajesh Agarwal
- Active roles for inhibitory κ B kinases α and β in nuclear factor- κ B-mediated chemoresistance to doxorubicin**1827
Brian K. Bednarski, Xiaoyu Ding, Kavita Coombe, Albert S. Baldwin, and Hong J. Kim
- Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models**1836
Dimitri Pchejetski, Nicolas Doumerc, Muriel Golzio, Maria Naymark, Justin Teissié, Takafumi Kohama, Jonathan Waxman, Bernard Malavaud, and Olivier Cuvillier

contents continued

Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells	1846
Dongwei Zhang, Ashutosh Pal, William G. Bornmann, Fumiyuki Yamasaki, Francisco J. Esteva, Gabriel N. Hortobagyi, Chandra Bartholomeusz, and Naoto T. Ueno	
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent <i>in vivo</i> antitumor activity	1851
Sauveur-Michel Maira, Frédéric Stauffer, Josef Brueggen, Pascal Furet, Christian Schnell, Christine Fritsch, Saskia Brachmann, Patrick Chène, Alain De Pover, Kevin Schoemaker, Dorian Fabbro, Daniela Gabriel, Marjo Simonen, Leon Murphy, Peter Finan, William Sellers, and Carlos García-Echeverría	
Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiation	1864
Atsushi Tomioka, Motoyoshi Tanaka, Marco A. De Velasco, Satoshi Anai, Satoshi Takada, Toshihiro Kushibiki, Yasuhiko Tabata, Charles J. Rosser, Hirotsugu Uemura, and Yoshihiko Hirao	
A novel combination: ranpirnase and rosiglitazone induce a synergistic apoptotic effect by down-regulating Fra-1 and Survivin in cancer cells	1871
Maria E. Ramos-Nino and Benjamin Littenberg	
Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor	1880
Andrea J. Gonzales, Kenneth E. Hook, Irene W. Althaus, Paul A. Ellis, Erin Trachet, Amy M. Delaney, Patricia J. Harvey, Teresa A. Ellis, Danielle M. Amato, James M. Nelson, David W. Fry, Tong Zhu, Cho-Ming Loi, Stephen A. Fakhoury, Kevin M. Schlosser, Karen E. Sexton, R. Thomas Winters, Jessica E. Reed, Alex J. Bridges, Daniel J. Lettiere, Deborah A. Baker, Jianxin Yang, Helen T. Lee, Haile Tecle, and Patrick W. Vincent	
Single-chain antibody/activated BID chimeric protein effectively suppresses HER2-positive tumor growth	1890
Xiu-Chun Qiu, Yan-Ming Xu, Fang Wang, Qing-Yu Fan, Li-Feng Wang, Bao-An Ma, Lin-Tao Jia, Jing Zhao, Yan-Ling Meng, Li-Bo Yao, Si-Yi Chen, and An-Gang Yang	
Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer	1900
Danica L. Rowe, Tuba Ozbay, Laura M. Bender, and Rita Nahta	
c-Jun knockdown sensitizes osteosarcoma to doxorubicin	1909
Crispin R. Dass, Levon M. Khachigian, and Peter F.M. Choong	
Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis	1913
Laura P. Stabile, Mary E. Rothstein, Phouthone Keohavong, Jide Jin, Jinling Yin, Stephanie R. Land, Sanja Dacic, The Minh Luong, K. Jin Kim, Austin M. Dulak, and Jill M. Siegfried	

Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model	1923
Akihiko Miyanaga, Akihiko Gemma, Rintaro Noro, Kiyoko Kataoka, Kuniko Matsuda, Michiya Nara, Tetsuya Okano, Masahiro Seike, Akinobu Yoshimura, Akiko Kawakami, Haruka Uesaka, Hiroki Nakae, and Shoji Kudoh	
Array-based analysis of the effects of trichostatin A and CG-1521 on cell cycle and cell death in LNCaP prostate cancer cells	1931
Somdutta Roy, Randy Jeffrey, and Martin Tenniswood	
Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis	1940
Marianne Kraus, Elke Malenke, Jeannette Gogel, Holger Müller, Thomas Rückrich, Herman Overkleeft, Huib Ovaa, Ewa Koscielniak, Jörg Thomas Hartmann, and Christoph Driessen	
Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-κB and activator protein-1 related mechanisms	1949
Zhong Chen, Justin L. Ricker, Pramit S. Malhotra, Liesl Nottingham, Lorena Bagain, Tin Lap Lee, Ning T. Yeh, and Carter Van Waes	
Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity	1961
Richard Sullivan, Geneviève C. Paré, Lisa J. Frederiksen, Gregg L. Semenza, and Charles H. Graham	
Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1α and-2α	1974
Maura Puppo, Florinda Battaglia, Catherine Ottaviano, Silvana Delfino, Domenico Ribatti, Luigi Varesio, and Maria Carla Bosco	
HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair	1985
Thuy T. Koll, Steven S. Feis, Mollie H. Wright, Modupe M. Teniola, Mekel M. Richardson, Ana I. Robles, John Bradsher, Jacek Capala, and Lyuba Varticovski	
S1P differentially regulates migration of human ovarian cancer and human ovarian surface epithelial cells	1993
Dongmei Wang, Zhenwen Zhao, Andrea Caperell-Grant, Gong Yang, Samuel C. Mok, Jinsong Liu, Robert M. Bigsby, and Yan Xu	
Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase	2003
Tatiana Okouneva, Olga Azarenko, Leslie Wilson, Bruce A. Littlefield, and Mary Ann Jordan	
Small-molecule inhibitor of the AP endonuclease 1/REF-1 E3330 inhibits pancreatic cancer cell growth and migration	2012
Gang-Ming Zou and Anirban Maitra	

Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression	2022
Jimmy M-M. Kwok, Stephen S. Myatt, Charles M. Marson, R. Charles Coombes, Demetra Constantinidou, and Eric W-F. Lam	
Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity	2033
Lourdes Roque-Navarro, Krittalak Chakrabandhu, Joel de León, Sandra Rodríguez, Carlos Toledo, Adriana Carr, Cristina Mateo de Acosta, Anne-Odile Hueber, and Rolando Pérez	
Chemoprevention by perillyl alcohol coupled with viral gene therapy reduces pancreatic cancer pathogenesis	2042
Irina V. Lebedeva, Zhao-zhong Su, Nichollaq Vozhilla, Lejuan Chatman, Devanand Sarkar, Paul Dent, Mohammad Athar, and Paul B. Fisher	
Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968	2051
Claudio Pisano, Michelandrea De Cesare, Giovanni Luca Beretta, Valentina Zuco, Graziella Pratesi, Sergio Penco, Loredana Vesci, Rosanna Foderà, Fabiana Fosca Ferrara, Mario Bernardino Guglielmi, Paolo Carminati, Sabrina Dallavalle, Gabriella Morini, Lucio Merlini, Augusto Orlandi, and Franco Zunino	
Arsenic trioxide enhances the therapeutic efficacy of radiation treatment of oral squamous carcinoma while protecting bone	2060
Pawan Kumar, Qinghong Gao, Yu Ning, Zhuo Wang, Paul H. Krebsbach, and Peter J. Polverini	
Proteomic characterization of cytoskeletal and mitochondrial class III β-tubulin	2070
Lucia Cicchillitti, Roberta Penci, Michela Di Michele, Flavia Filippetti, Domenico Rotilio, Maria Benedetta Donati, Giovanni Scambia, and Cristiano Ferlini	
Antiangiogenic vinflunine affects EB1 localization and microtubule targeting to adhesion sites	2080
Stéphane Honoré, Alessandra Pagano, Géraldine Gauthier, Véronique Bourgarel-Rey, Pascal Verdier-Pinard, Karine Civiletti, Anna Kruczynski, and Diane Braguer	
Cyclooxygenase inhibitors block uterine tumorigenesis in <i>HMGA1a</i> transgenic mice and human xenografts	2090
Francescopaolo Di Cello, Joelle Hillion, Jeanne Kowalski, Brigitte M. Ronnett, Abimbola Aderinto, David L. Huso, and Linda M.S. Resar	
Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-α-dependent and estrogen receptor-α-independent mechanisms	2096
Xinghua Long, Meiyun Fan, Robert M. Bigsby, and Kenneth P. Nephew	
5,5'-Dibromo-bis(3'-indolyl)methane induces Krüppel-like factor 4 and p21 in colon cancer cells	2109
Sung Dae Cho, Sudhakar Chintharlapalli, Maen Abdelrahim, Sabitha Papineni, Shengxi Liu, Jingjing Guo, Ping Lei, Ala Abudayyeh, and Stephen Safe	

Differential antiproliferative mechanisms of novel derivative of benzimidazo[1,2-α]quinoline in colon cancer cells depending on their p53 status	2121
Mirela Sedic, Miroslav Poznic, Peter Gehrig, Mike Scott, Ralph Schlapbach, Marijana Hranjec, Grace Karminski-Zamola, Kresimir Pavelic, and Sandra Kraljevic Pavelic	
Antimigratory effect of TK1-2 is mediated in part by interfering with integrin $\alpha_2\beta_1$	2133
Hyun-Kyung Kim, Dae-Shik Oh, Sang-Bae Lee, Jung-Min Ha, and Young Ae Joe	
Prostate-specific membrane antigen associates with anaphase-promoting complex and induces chromosomal instability	2142
Sigrid A. Rajasekaran, Jason J. Christiansen, Ingrid Schmid, Eri Oshima, Kathleen Sakamoto, Jasminder Weinstein, Nagesh P. Rao, and Ayyappan K. Rajasekaran	
Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin	2152
Olga Kovalchuk, Jody Filkowski, James Meservy, Yaroslav Ilnytsky, Volodymyr P. Tryndyak, Vasyly F. Chekhun, and Igor P. Pogribny	
RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis	2160
Robert E. Miller, Martine Roudier, Jon Jones, Allison Armstrong, Jude Canon, and William C. Dougall	
Andrographolide sensitizes cancer cells to TRAIL-induced apoptosis via p53-mediated death receptor 4 up-regulation	2170
Jing Zhou, Guo-Dong Lu, Chye-Sun Ong, Choon-Nam Ong, and Han-Ming Shen	
Cloning and apoptosis-inducing activities of canine and feline TRAIL	2181
Sing Rong, Jenny H. Cai, and Jennifer Andrews	
Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa	2192
Yang Meng, Wenhua Tang, Yao Dai, Xiaoqing Wu, Meilan Liu, Qing Ji, Min Ji, Kenneth Pienta, Theodore Lawrence, and Liang Xu	
Down-regulation of X-linked inhibitor of apoptosis synergistically enhanced peroxisome proliferator-activated receptor γ ligand-induced growth inhibition in colon cancer	2203
Liang Qiao, Yun Dai, Qing Gu, Kwok Wah Chan, Bing Zou, Juan Ma, Jide Wang, Hui Y. Lan, and Benjamin C.Y. Wong	
The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor-induced apoptosis	2212
Shruti M. Raja, Shuzhen Chen, Ping Yue, Timothy M. Acker, Benjamin Lefkove, Jack L. Arbiser, Fadlo R. Khuri, and Shi-Yong Sun	
Key role for Bak activation and Bak-Bax interaction in the apoptotic response to vinblastine	2224
Meenakshi Upreti, Rong Chu, Elena Galitovskaya, Sherri K. Smart, and Timothy C. Chambers	


Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids2233
Margaret E. Ackerman, David Pawlowski, and K. Dane Wittrup

A rationally designed tyrosine hydroxylase DNA vaccine induces specific antineuroblastoma immunity2241
Nicole Huebener, Stefan Fest, Anne Strandsby, Elke Michalsky, Robert Preissner, Yan Zeng, Gerhard Gaedicke, and Holger N. Lode

Synergistic tumoricidal effect of combined hMUC1 vaccination and hNIS radioiodine gene therapy2252
Yong Hyun Jeon, Yun Choi, Sun Och Yoon, Chul Woo Kim, and June-Key Chung

Correction

Article on CIC-3 and cancer drug resistance2261



On the Cover

The structure of NVP-BEZ235 alone (top) or docked in the catalytic site of PI3K α (bottom). The model was generated using the coordinates of known PI3K γ crystal structures. All possible orientations were considered to determine which one was the most consistent with the available structure-activity relationship, in particular with regard to the importance of the hydrogen bond acceptor nitrogen atoms present in the chemical structure of the inhibitor for high potency. For details, see Maira et al., in this issue.